GSK launches $2.5 billion buyback, lifts sales target after stellar fourth quarter
GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...
FiercePharma9d
With Blenrep's revival, GSK dials up long-term sales goal—again—despite RSV vaccine woes
The latest increase reflects the revival of the once-withdrawn antibody-drug conjugate Blenrep, as well as “multiple launch opportunities in the ’26-to-’31 period,” GSK CEO Emma Walmsley ...
Drug developer GSK leaving 635K sf life sciences lab near DC
Drug developer GSK is vacating its 635,000-square-foot life sciences lab in Rockville, Maryland, where it was the sole tenant ...
Arizona says GlaxoSmithKline's greed endangered kids with asthma
GlaxoSmithKline "deliberately" discontinued a widely-used asthma medication in order to reap profits and families suffered, ...
GSK Surges 8% After Bumping Its 2031 Outlook To North Of $50 Billion
GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 ...
GSK Stock Jumps on Long-Term Outlook Boost, $2.5B Share Buyback Plan
GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the back of optimism about sales of its new drugs ...
Seeking Alpha9d
GSK outlines 2025 growth driven by specialty medicines and new product launches
CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit grew 13%, supporting a ...